Cameron Turtle
Known title: Chief Executive OfficerCIK: 0001758363
Associated companies
Transaction History
| SYRE | ▼ Sell | Open Market | 600 | $53K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,683 | $242K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,638 | $241K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,989 | $368K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 4,990 | $466K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 100 | $9K | 10/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 8,400 | $732K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,700 | $326K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 400 | $36K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,500 | $216K | 9/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 800 | $75K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 7,157 | $681K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,635 | $541K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,392 | $135K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 16 | $2K | 8/3/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 10,176 | $890K | 7/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 4,234 | $373K | 7/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 590 | $52K | 7/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,557 | $247K | 6/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 8,149 | $575K | 6/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,294 | $235K | 6/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,300 | $369K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,600 | $255K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,000 | $72K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 3,100 | $227K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 1,700 | $126K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 300 | $22K | 5/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,656 | $133K | 4/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 12,344 | $607K | 4/1/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,900 | $246K | 3/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 9,100 | $387K | 3/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 957 | $30K | 2/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 14,043 | $462K | 2/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 12,709 | $387K | 1/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 2,191 | $70K | 1/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 100 | $3K | 1/2/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 10,995 | $316K | 12/1/2025 | View on chart |
| SYRE | ▼ Sell | Open Market | 4,005 | $119K | 12/1/2025 | View on chart |
| SYRE | ▼ Sell | Open Market | 28,155 | $651K | 11/3/2025 | View on chart |
| SYRE | ▼ Sell | Open Market | 16,845 | $399K | 11/3/2025 | View on chart |
| SYRE | ▲ Buy | Grant | 400 | $4K | 2/15/2024 | View on chart |
| SYRE | ▼ Sell | Other | 723,440 | $0 | 11/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.